Expression profiling of transcription factors in B-or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: Usefulness of PAX5 immunostaining as pan-pre-B-cell marker

American Journal of Clinical Pathology

Volumn 133, Issue 1, 2010, Pages 41-48

  Nasr, Michel R ^a   Rosenthal, Nancy ^a   Syrbu, Sergei ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

B cell transcription factors; B T ALL; Burkitt lymphoma; Pan B cell markers

Indexed keywords

CD20 ANTIBODY; CD22 ANTIGEN; CD79A ANTIGEN; INTERFERON REGULATORY FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BOB 1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B ACUTE LYMPHOBLASTIC LEUKEMIA; B ACUTE LYMPHOBLASTIC LYMPHOMA; BURKITT LYMPHOMA; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; T ACUTE LYMPHOBLASTIC LEUKEMIA; T ACUTE LYMPHOBLASTIC LYMPHOMA; TISSUE MICROARRAY;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; BONE MARROW CELLS; BURKITT LYMPHOMA; CELL LINEAGE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 73949141190     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPYP00JNUFWCCY     Document Type: Article

References (29)

1. Kaleem Z, White G, Zutter MM. Aberrant expression of T-cell - associated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol. 2001;115:396-403.
2. Yao X, Teruya-Feldstein J, Raffeld M, et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14:105-110.
3. Yokose N, Ogata K, Sugisaki Y, et al. CD20-positive T cell leukemia/lymphoma: case report and review of the literature. Ann Hematol. 2001;80:372-375.
4. Tzankov AS, Went PT, Münst S, et al. Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol. 2007;20:632-637.
5. Chu PG, Loera S, Huang Q, et al. Lineage determination of CD20- B-cell neoplasms: an immunohistochemical study. Am J Clin Pathol. 2006;126:534-544.
6. Brunning RD, Borowitz M, Matutes E, et al. Precursor B-cell and T-cell neoplasms. In: Jaffe ES, Harris NC, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:109-115. World Health Organization Classification of Tumours.
7. Adams B, Dörfler P, Aguzzi A, et al. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev. 1992;6:1589-1607.
8. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 1998;92:1308-1316.
9. Nutt SL, Heavey B, Rolink AG, et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 1999;401:556-562.
10. Browne P, Petrosyan K, Hernandez A, et al. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol. 2003;120:767-777.
11. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood. 2002;99:409-426.
12. Tiacci E, Pileri S, Orleth A, et al. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res. 2004;64:7399-7404.
13. Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343-1350.
14. Zhang X, Lin Z, Kim I. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. J Korean Med Sci. 2003;18:804-808.
15. Valbuena JR, Medeiros LJ, Rassidakis GZ, et al. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2006;126:235-240.
16. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21) (q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470-477.
17. Lagergren A, Manetopoulos C, Axelson H, et al. Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression. BMC Cancer. 2004;4:80. doi:10.1186/1471-2407-4-80.
18. Mhawech-Fauceglia P, Saxena R, Zhang S, et al. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol. 2007;60:709-714.
19. Dong HY, Liu W, Cohen P, et al. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in Merkel cell carcinoma and small cell carcinomas. Am J Surg Pathol. 2005;29:687-692.
20. Sullivan LM, Atkins KA, Legallo RD. PAX immunoreactivity identifies alveolar rhabdomyosarcoma. Am J Surg Pathol. 2009;33:775-780.
21. Koyama M, Ishihara K, Karasuyama H, et al. CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int Immunol. 1997;9:1767-1772.
22. Pilozzi E, Pulford K, Jones M, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998;186:140-143.
23. Pilozzi E, Müller-Hermelink HK, Falini B, et al. Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol. 1999;188:267-270.
24. Sáez AI, Artiga MJ, Sánchez-Beato M, et al. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas. Mod Pathol. 2002;15:211-220.
25. Marafioti T, Ascani S, Pulford K, et al. Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms. Am J Pathol. 2003;162:861-871.
26. McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol. 2006;19:1010-1018.
27. Erickson LD, Tygrett LT, Bhatia SK, et al. Differential expression of CD22 (Lyb8) on murine B cells. Int Immunol. 1996;8:1121-1129.
28. Boué DR, LeBien TW. Expression and structure of CD22 in acute leukemia. Blood. 1988;71:1480-1486.
29. Janossy G, Coustan-Smith E, Campana D. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia. 1989;3:170-181.